Suppr超能文献

患有 2 型糖尿病的医学管理受试者中的急性冠脉综合征风险 - ASCVD 风险评分在这里失效了吗?

The Acute Coronary Syndrome Risk in Medically Managed Subjects with Type 2 Diabetes Mellitus - Is the ASCVD Risk Score Failing Here?

机构信息

Department of Endocrinology, Bhaktivedanta Hospital and Research Institute, Maharashtra, India.

Department of Cardiology, Bhaktivedanta Hospital and Research Institute, Maharashtra, India.

出版信息

J ASEAN Fed Endocr Soc. 2024;39(1):31-36. doi: 10.15605/jafes.039.01.15. Epub 2024 Feb 5.

Abstract

OBJECTIVES

Type 2 Diabetics have elevated risk for acute coronary syndrome (ACS). The current management algorithm focuses on atherosclerotic cardiovascular (ASCVD) risk score to stratify this risk. However, in medically managed subjects, this algorithm may not be accurate. This study compares the ASCVD risk score in an Indian population with T2DM under medical supervision and the actual incidence of ACS. It also compared the ASCVD risk scores in cases with T2DM who developed ACS to controls and tried to estimate whether the ASCVD risk score is different in the two subsets, evaluating the utility of the ASCVD risk score in predicting ACS.

METHODOLOGY

This is an electronic medical record (EMR) based case-control study. Only records of subjects with T2DM where details of age, sex, body mass index, blood pressure, duration of diabetes, family history of ACS, lipid profile, renal and liver function tests were included. The incidence of ACS was calculated in the selected records, and the records of subjects with ACS were compared with age and sex-matched subjects without ACS. Data are summarized as median and interquartile range (IQR). Wilcoxon rank-sum test was used for checking differences in continuous variables and Pearson's Chi-squared test for categorical data. Univariate and multivariate logistic regression analyses were used to check the effect of ASCVD scores and other variables on the occurrence of ACS.Statistical data analyses were performed using JASP, version 0.16.4 (JASP Team [2022]) for MS Windows.

RESULTS

Of the 1226 EMRs included in the analysis, 207 had ACS. The actual incidence of ACS was 16.85% in 6 years, higher than the mean predicted 10-year incidence of 14.56 percent ( <0.05). The cases were age and sex-matched with controls and the ASCVD incidence was estimated in the two groups. The mean ASCVD score in the cases was 14.565 ± 8.709 (Min: 1.5, Max: 38.3) and controls 13.114 ± 8.247 (Min: 1.4, Max: 45). The chance of development of ACS increases with elevated systolic blood pressure (per mmHg rise OR: 1.04, 95% CI: 1.03, 1.06; <0.001), positive family history (OR: 5.70, 95% CI: 3.41, 9.77; <0.001), statin use (OR: 2.26, 95% CI: 1.46, 3.52; <0.001), and longer duration of diabetes (for every year increase OR: 1.19, 95% CI: 1.13, 1.25; <0.001).

CONCLUSION

The ASCVD risk score underestimates the ACS risk in subjects with T2DM under medical supervision and may not differ in those who developed and did not develop ACS. We also conclude that factors like a negative family history (30% less risk), longer duration of diabetes, and higher SBP are relevant in those who developed ACS.

摘要

目的

2 型糖尿病患者发生急性冠状动脉综合征(ACS)的风险较高。目前的管理算法侧重于动脉粥样硬化性心血管疾病(ASCVD)风险评分来分层这种风险。然而,在接受药物治疗的患者中,这种算法可能并不准确。本研究比较了在医学监督下患有 T2DM 的印度人群的 ASCVD 风险评分与 ACS 的实际发生率。它还比较了发生 ACS 的 T2DM 患者与对照组的 ASCVD 风险评分,并试图估计 ASCVD 风险评分在这两个亚组中的差异,评估 ASCVD 风险评分在预测 ACS 中的效用。

方法

这是一项基于电子病历(EMR)的病例对照研究。仅包括 T2DM 患者的记录,详细记录了年龄、性别、体重指数、血压、糖尿病病程、ACS 家族史、血脂谱、肝肾功能检查等信息。在选定的记录中计算 ACS 的发生率,并将 ACS 患者的记录与年龄和性别匹配的无 ACS 患者的记录进行比较。数据总结为中位数和四分位距(IQR)。Wilcoxon 秩和检验用于检查连续变量的差异,Pearson's Chi-squared 检验用于分类数据。使用单变量和多变量逻辑回归分析检查 ASCVD 评分和其他变量对 ACS 发生的影响。统计数据分析使用 JASP,版本 0.16.4(JASP 团队[2022])用于 MS Windows。

结果

在纳入分析的 1226 份 EMR 中,有 207 份发生 ACS。6 年内 ACS 的实际发生率为 16.85%,高于平均预测的 10 年发生率 14.56%(<0.05)。病例与对照组按年龄和性别匹配,估计两组的 ASCVD 发生率。病例组的平均 ASCVD 评分为 14.565±8.709(最小值:1.5,最大值:38.3),对照组为 13.114±8.247(最小值:1.4,最大值:45)。随着收缩压升高(每升高 1mmHg,OR:1.04,95%CI:1.03,1.06;<0.001)、阳性家族史(OR:5.70,95%CI:3.41,9.77;<0.001)、他汀类药物使用(OR:2.26,95%CI:1.46,3.52;<0.001)和糖尿病病程延长(每年增加,OR:1.19,95%CI:1.13,1.25;<0.001),发生 ACS 的几率增加。

结论

在接受药物治疗的 T2DM 患者中,ASCVD 风险评分低估了 ACS 风险,并且在发生和未发生 ACS 的患者中可能没有差异。我们还得出结论,家族史阴性(风险降低 30%)、糖尿病病程较长和较高的 SBP 等因素与发生 ACS 的患者相关。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/033f/11163319/57fe5a1d1b0d/JAFES-39-1-31-g001.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验